Premium
Circulating form of human vascular adhesion protein‐1 (VAP‐1): Decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis
Author(s) -
Toiyama Yuji,
Miki Chikao,
Inoue Yasuhiro,
Kawamoto Aya,
Kusunoki Masato
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21246
Subject(s) - medicine , colorectal cancer , lymphatic system , predictive marker , metastasis , cancer , adhesion , oncology , pathology , chemistry , organic chemistry
Background and Objectives Vascular adhesion protein‐1 (VAP‐1) is an endothelial cell molecule that controls leukocyte tissue infiltration. Elevated serum soluble VAP‐1 (sVAP‐1) has been described in certain diseases with an inflammatory component. However, sVAP‐1 expression or function has not been studied in colorectal cancer. The present study determined the relationships between preoperative serum sVAP‐1 and clinicopathological features and prognosis in colorectal cancer. Methods One hundred patients with histologically proven colorectal cancer and 33 normal volunteers were included. Preoperative serum was collected, and sVAP‐1 levels were assayed by enzyme‐linked immunosorbent assay. Results Mean sVAP‐1 level in patients was significantly higher than in controls, and decreased with disease progression. Mean sVAP‐1 level was significantly correlated with venous invasion, lymph node metastasis, distant metastasis including hepatic metastasis, and advanced TNM classification. Furthermore, sVAP‐1 was an independent marker for predicting lymph node or hepatic metastasis. Prognosis of patients with a lower sVAP‐1 level was significantly worse than those with elevated sVAP‐1. Conclusions Preoperative low sVAP‐1 level is associated with poor prognosis in colorectal cancer. Measuring serum sVAP‐1 may provide valuable information in predicting patients with lymph node or hepatic metastasis. J. Surg. Oncol. 2009;99:368–372. © 2009 Wiley‐Liss, Inc.